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The demonstration of the importance of histamine in anaphylaxis and allergic
mechanisms has recently stimulated an extraordinary amount of research and
investigation in an attempt to find effective non-toxic "histamine antagonists."
The amino-acids, arginine, cysteine, and histidine, do, to a certain extent, in-
hibit the action of histamine on guinea pigs in vivo and in vitro but are too toxic
for clinical use and oniy slightly active.
The early French synthetics, the phenolic ethers and ethylenediamines of
Fourneau and Bovet (1933) are more active but too toxic for therapeutic use.
The newer histamine antagonists, while quite effective, are less toxic and have,
therefore, been used extensively in clinical investigation and therapeutically.
The chemical similarity and dissimilarity of the antihistaminic compounds and
their relationship to pharmacological activity has been discussed elsewhere (1).
Benadryl and Pyribenzamine which have had a wide clinical trial, exhibit a
high incidence of side actions (2). With Benadryl particularly, about 50 per cent
of the patients manifest these to some extent. The most commonly encountered
untoward effects are those of drowsiness and sedation, often of sufficient inten-
sity to interfere with the patient's normal activities and, therefore, seriously
restrict the drug's usefulness. Other common side-effects are vertigo, dryness of
the mouth, nausea, insomnia, hot flushes and aggravation of a previously exist-
ing allergy.
Pyribenzamine is on the average better tolerated in larger doses than l3ena-
dryl, but it too has a high incidence of side effects, about 25 per cent of the pa-
tients evidencing reactions of moderate intensity. Drowsiness, gastrointestinal
symptoms, vertigo and nervousness are most frequent with dryness of the
mouth and palpitation next in order (3).
Laboratory studies of subjects to whom these drugs were given have been re-
ported by several investigators. Weekly urinalysis and blood counts on 56
patients receiving 50 to 300 mgm. of Pyribenzamine daily for periods ranging
from a few days to several months were reported by Baer and Sulzberger (4).
These showed no deviation from normal. Koepf, Arbesman and Munafo (5) did
intensive laboratory studies on 3 healthy men who were given 150 mgm. of Py-
ribenzamine daily for 80 days. Urine examinations, blood counts, blood chemis-
try determinations and renal and hepatic function remained normal.
Because of the comparatively high incidence of side-actions even with the
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newer histamine antagonists, the search for more effective and less toxic "anti-
histaminics" continues. Recently a new ethylenediamine derivative has been
synthesized; one which has remarkably low toxicity as indicated by preliminary
laboratory investigation, and an activity equivalent to that of the best prepara-
tions at present in clinical use. This is Diatrin Hydrochloride, (N ,N-dimethyl-
N'phenyl N'- (2-thienylmethyl) ethylenediamine monohydrochioride).
Pharmacologic studies by Ercoli et al. (6) demonstrate that Diatrin Hydro-
chloride is an effective histamine antagonist, preventing histaminic asthma and
contraction of isolated guinea-pig intestine. In the same dosages as Pyribenza-
mine and Benadryl it was much better tolerated by a variety of laboratory ani-
mals, the oral doses required for convulsive seizures, for example, being much
higher. They conclude that Diatrin Hydrochloride is oniy one-half to one-third
as toxic as Benadryl, Pyribenzamine, Antergan and Neo-antergan, with which
it was compared.
It was decided to conduct a clinical investigation in order to determine toxicity
in man and the incidence and nature of any side effects. This was done on the
dermatologic wards of Bellevue Hospital, U. S. Marine Hospital, Staten Island,
N. Y., and Veterans Hospital, Bronx, N. Y.
METHOD
Seventy-two patients were included in the series, 6 women and 66 men, rang-
ing in age from twenty to seventy-five years. All had been hospitalized for a
wide variety of dermatoses. Selection was made at random with no regard for
their allergic status. All were generally in good health except for the cutaneous
pathology.
Diatrin Hydrochloride was used in 50 milligram tablets, both plain and sugar
coated.
The dosage varied from 100 to 1,000 milligrams daily, for periods from 48
hours to 82 days. The average duration of treatment was 19.2 days, with 35 sub-
jects receiving the drug longer than 2 weeks, and 13 patients receiving 1,000
milligrams a day. The minimum total dosage was 200 mgm., and the maximum
48,300 mgm., with 22 subjects getting 10,000 mgm. or more.
Clinical data were gathered by observation for signs and symptoms of intol-
erance and idiosyncrasy. Subjective symptoms were described by the patients,
leading questions being avoided.
The laboratory data for each patient included the following, done at the onset
of the investigation, at its conclusion and at weekly intervals throughout its
course; a complete urinalysis, including microscopic examination of the centri-
fuged sediment, a determination of the hemoglobin, red and white cell count,
differential and platelet counts. In addition urinary output was measured daily
and the icteric index determined at the onset and conclusion of the investigation.
RESULTS
Laboratory data—The urine showed no change and the urinary output con-
tinued normal. The icteric indices were unaltered. Red cell count, hemoglobin
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TABLE I
Final Laboratory Data on subjects on 1,000 mgm. daily dosage with total dosage of over
p5,000 mgm.
AGE SEX
REMO-
GS.OBIN
GRAMS
RED
BLOOD
CELLS,
MIL-
LIONS
WRITE
BLOOD
CELLS
LYSIPRO-
CYTES
MONO-
CYTES
POLY-
MOE-
PRONU
CLEAR
TOTAL
POLY-
PRONUC-
LEAR
POLY-()
CLEAR
MATURE
ZOSINO-
SMILES
BASO-
SMILES PLATELETS
57 M 13.5 4.04 5700 35 10 54 6 48 1 — 120,000
21 M 13.5 4.02 7400 10 8 80 4 76 2 — 120,000
64 M 13.5 4.10 5500 22 10 67 8 59 1 — 152,000
62 M 13.0 4.18 7600 20 4 71 8 63 10 — 192,500
31 M 14.5 4.16 5400 20 10 68 7 61 1 1 167,000
Results of examinations before inception and at weekly intervals during administration
of drug were all normal; values being very close to those given above.
TABLE II
Side Effects (in order of frequency)
Fifteen (15) patients exhibited one or more of the following.
Nausea 7
Emesis 4
Urinary frequency 4*
Fever 3
Diarrhea 1
Urinary urgency 1
Headache 1
Drowsiness 1—
* One of these patients on sugar-coated diatrin. All other side effects from plain diatrin.
—First day only.
N. B.
1) One patient with nausea from plain diatrin on 800 mgm. per day given sugar-coated
diatrin, 1,000 mgm. daily with no further nausea.
2) One patient with fever (101° to 103°F.) while on plain diatrin 200 mgm. per day, was
given 600 mg daily of same preparation with no further elevation of temperature.
TABLE 1111
Side Effects in. relation to Dosage and Preparation
DURATION 01'
DIATRIN (PLAIN)
100-300 MOM. MAXIMUM
DAILY DOSE
DIATRIN (SUGAR-COATED)
100-300 MOM. MAXIMUM
DAILY DOSE
DIATSSIN (PLAIN)
400-1,000 MOM. MAXIMUM
DAILY DOSE
ISIATRIN (SUGAR-COATED)
400-1000 MOM. MAXIMUM
DAILY DOSE
TREATMENT
IN DAYS
No. of
patients
.No. with
side-effects
No. of
patients
.No. with
side-effects
No. of
patients
.No. with
side-effects
No. of
patients
.No. with
side-effects
2—7 11 2 3 — — — 1 —
8—14 12 2 — — 14 2 9 —
15—21 1 1 — — 4 2 8 —
22—28 3 1 — — 4 1 6 1*
29—60 2 1 1 1 6 3 2 —
*This patient had no clinical side-effects, but a reduction in polymorphonuclear cells
although total white blood count remained normal.
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and white cell count remained normal. One patient receiving 1,000 mgm. daily
exhibited a fall in the polymorphonuclear neutrophils to 34 per cent although
the total white count remained normal (6,300). This occurred after 21 days and
a total dosage of 11,800 mgm n one patient an eosinophilia of 24 per cent was
observed on the 23rd day. This was associated with emesis and might possibly
be construed as evidence of a gastrointestinal allergy.
TABLE W
Analysis of side effects According to Dosage
5!ThBEP OP DA(S VMBEROF NUMBER WIIR TtPE OP SZDE RFPECTS
Diatrin (plain)—100 to 350 mgm. maximum daily dosage
2— 7 11 2 1 urinary frequency
1 drowsiness (first day only)
8—14 12 2 1 vomiting and fever
1 nausea, vomiting and diarrhea
15—21 1 1 nausea and vomiting
22-28 3 1 vomiting
29—60 2 —
Diatrin (plain)—400 to 1,000mgm. maximum daily dosage
2—7 — —
8—14 14 2 1 fever
1 nausea and fever
15—21 4 2 1 nausea
1 urinary frequency and urgency; nausea
22—28 4 1 nausea
29—60 6 3 1 nausea
2 urinary frequency
Total 57 14
No relationship between dosage and type of side effect.
The platelet determinations were done by a counting chamber method, the
standard deviation being 50,000. Alterations in our values, therefore, fell
within the standard deviation. In almost all cases, however, our original figures
taken before therapy was instituted were somewhat lower than normal (Table I).
Clinical data—There was no evidence of serious or lasting toxicity, nor any
effect on blood pressure. The side effects (see Table II) were mostly gastrointes-
tinal, and could in some cases, be attributed to the bitter taste of the Diatrin. It
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was for this reason that the plain tablets were replaced by sugar coated tablets.
Thereafter no patient complained of bitterness, nor was there any further nau-
sea or vomiting. For example, one patient complaining of nausea while receiving
800 mgm. per day of the plain Diatrin was given 1,000 mgm. daily of the sugar
coated tablets with no further complaints (see Table II). It is difficult to explain
the sharp drop in incidence of all side effects with the introduction of the sugar
coated tablet (see Table III).
There was no relationship between dosage and the type of side effects (Table
IV) nor between dosage and the onset of side effects (Table V).
Of a total of 72 patients (Table VI), 57 showed no side effects and of the re-
maining 15, only five had side effects severe enough to require cessation of the
drug.
TABLE V
Distribution of patients according to maximum. daily dosage and onset of side effects
MDV. PER DAY 100 200
14
300
3
400
24
600
3
800
4
1,000
13
TOTAL
72Number of patients 11
Number of patients in whom side
effects first became apparent 2 7 0 2 1 2 1* 15
* Only side effect from sugar-coated tablet.
All others from plain tablets.
There was no direct relationship between dosage and side effects although the tolerance
of individual patients does vary.
TABLE VI
Side Effects from Diatrin Hydrochloride
NUMBER OF PATIENTS NONE SLIGHT MODERATE SEVERE
72 57 7 3 5
SUMMARY AND CONCLUSIONS
1. Diatrin Hydrochloride was administered to seventy-two subjects in daily
doses from 100 to 1,000 milligrams.
2. Thirteen of these received 1,000 milligrams each day.
3. No instance of serious or lasting toxicity was encountered.
4. The incidence of side effects was lower than has been reported with equiva-
lent doses of other histamine antagonists at present in general use.
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